Drug:
Reaction: MALIGNANT NEOPLASM PROGRESSION
20250101 - 20251231
No. 601 - 700
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 601 | 25013910 |
FR |
63 | 2 |
Malignant neoplasm progression, Drug ineffective, |
||||
AZACITIDINE, AZACITIDINE FOR, LENALIDOMIDE, ERYTHROPOIETIN, FLUDARABINE PHOSPHATE, BUSULFAN, |
||||
| 602 | 25013955 |
FR |
1 | |
Malignant neoplasm progression, Non-small cell lung cancer, Intentional product use issue, |
||||
CAPMATINIB, CAPMATINIB, CAPMATINIB, |
||||
| 603 | 25014131 |
JP |
9 | 1 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 604 | 25014158 |
SK |
74 | 1 |
Transient ischaemic attack, Multiple fractures, Malignant neoplasm progression, Off label use, |
||||
BEVACIZUMAB-AWWB, ATEZOLIZUMAB, |
||||
| 605 | 25014324 |
CA |
60 | 1 |
Sarcoma metastatic, Malignant neoplasm progression, Metastases to lung, Off label use, |
||||
PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, |
||||
| 606 | 25014374 |
JP |
64 | 1 |
Tumour lysis syndrome, Hypoalbuminaemia, Cytopenia, Cytokine release syndrome, Feeding disorder, Malignant neoplasm progression, Renal impairment, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, |
||||
| 607 | 25014385 |
US |
74 | 2 |
Squamous cell carcinoma of skin, Rheumatoid arthritis, Granulomatous dermatitis, Cataract, Pneumonia, Electrocardiogram QT prolonged, Deafness, Mycobacterium chelonae infection, Purulent discharge, Skin lesion, Soft tissue infection, Excessive granulation tissue, Deafness neurosensory, Malignant neoplasm progression, Skin hyperpigmentation, Dry skin, Pruritus, Tinnitus, Drug eruption, Nausea, Dizziness, Oral discomfort, Drug intolerance, Herpes simplex, Therapeutic product effect decreased, Cough, Decreased appetite, Decreased immune responsiveness, |
||||
AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, METHOTREXATE, METHOTREXATE SODIUM, CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFOLXACIN, CIPROFLOXACIN TABLETS, DOXYCYCLINE, DOXYCYCLINE HYCLATE, CLARITHROMYCIN, TIGECYCLINE, TOBRAMYCIN, TOBRAMYCIN SULFATE, TOBRAMYCIN SOLUTION, MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN, LINEZOLID, LINEZOLID, VALACYCLOVIR HYDROCHLORIDE, SULFAMETHOXAZOLE AND TRIMETHOPRIM, AMOXICILLIN AND CLAVULANATE POTASSIUM, AMIKACIN, CEFOXITIN, CEFOXITIN SODIUM, OMADACYCLINE, HYDROXYCHLOROQUINE, IMIQUIMOD, ATORVASTATIN CALCIUM, OMADACYCLINE, LEVOTHYROXINE SODIUM, GABAPENTIN, CYCLOSPORINE, TIGECYCLINE, |
||||
| 608 | 25015069 |
JP |
2 | |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 609 | 25015247 |
JP |
8 | 2 |
Death, Malignant neoplasm progression, Altered state of consciousness, Febrile neutropenia, Adrenal insufficiency, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, CARBOPLATIN, PACLITAXEL, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 610 | 25006759 |
GB |
18 | 1 |
Jaundice cholestatic, Malignant neoplasm progression, Pancreatitis acute, Off label use, |
||||
CABOZANTINIB, CABOZANTINIB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, PREGABALIN, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, MORPHINE SULFATE, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, BURN RELIEF, MAXIMUM STRENGTH PAIN RELIEVER, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, LIDOCAINE 4%, LIDOCAINE, MENTHOL, FUROSEMIDE, GLYCOPYRROLATE, LANSOPRAZOLE, PREGABALIN, PREGABALIN, DOCUSATE SODIUM, DOCUSATE SODIUM 100MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, LORAZEPAM, MIDAZOLAM, MIDAZOLAM HYDROCHLORIDE, MORPHINE SULFATE, |
||||
| 611 | 25006775 |
CA |
1 | |
Neoplasm malignant, Malignant neoplasm progression, Paraganglion neoplasm malignant, Metastases to lung, Skin lesion, Metastases to lymph nodes, |
||||
VINCRISTINE SULFATE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DACARBAZINE, EVEROLIMUS, |
||||
| 612 | 25006840 |
CA |
55 | 2 |
Nausea, Vomiting, Gallbladder cancer, Malignant neoplasm progression, |
||||
CAPMATINIB, CAPMATINIB, |
||||
| 613 | 25006872 |
JP |
53 | 1 |
Pneumothorax, Malignant neoplasm progression, |
||||
ZOLBETUXIMAB, FLUOROURACIL, LEVOLEUCOVORIN INJECTION, LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN, OXALIPLATIN, |
||||
| 614 | 25006931 |
US |
14 | 1 |
Pneumothorax, Hypothyroidism, Pneumothorax, Febrile neutropenia, Aortic valve incompetence, Cancer surgery, Pain, Pleural effusion, Malignant neoplasm progression, Osteosarcoma recurrent, Diarrhoea, Vomiting, Nausea, Palmar-plantar erythrodysaesthesia syndrome, Musculoskeletal pain, Back pain, Abdominal pain upper, Fatigue, Synovitis, Off label use, |
||||
CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, ERGOCALCIFEROL, CELECOXIB, ERGOCALCIFEROL, FAMOTIDINE, GABAPENTIN, IBUPROFEN SODIUM, IBUPROFEN, IBUPROFEN TABLETS, COATED, IBUPROFEN TABLET COATED, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE NASAL, NALOXONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE, POLYETHYLENE GLYCOL 3350, |
||||
| 615 | 25007763 |
FR |
81 | 1 |
Malignant neoplasm progression, Malignant pleural effusion, Atelectasis, Lung consolidation, Lung disorder, |
||||
ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, AMLODIPINE, RAMIPRIL, FERROUS SULFATE, SITAGLIPTIN AND METFORMIN HYDROCHLORIDE, MONTELUKAST SODIUM, ALLOPURINOL, FLUTICASONE FUROATE, RABEPRAZOLE, |
||||
| 616 | 25007972 |
IN |
57 | 1 |
Myelodysplastic syndrome with multilineage dysplasia, Malignant neoplasm progression, |
||||
ELTROMBOPAG, LENALIDOMIDE, |
||||
| 617 | 25008082 |
SI |
80 | 2 |
Malignant neoplasm progression, Metastases to stomach, Hormone receptor positive breast cancer, Weight decreased, Dysphagia, Anaemia, Dyspnoea, Carbohydrate antigen 15-3 increased, Oesophageal hypomotility, |
||||
LETROZOLE, LETROZOLE TABLETS, |
||||
| 618 | 25008244 |
JP |
8 | 2 |
Ascites, Metastases to peritoneum, Malignant neoplasm progression, |
||||
ZOLBETUXIMAB, OXALIPLATIN, NIVOLUMAB, RAMUCIRUMAB, IRINOTECAN HYDROCHLORIDE, |
||||
| 619 | 25008248 |
HR |
67 | 1 |
Asthenia, Visual impairment, Hypoacusis, Hepatitis, Myositis, Legionella infection, Acute respiratory distress syndrome, Pulmonary embolism, Polyuria, Off label use, Malignant neoplasm progression, |
||||
NIVOLUMAB, IPILIMUMAB, |
||||
| 620 | 25008272 |
GB |
||
Pancreatitis acute, Malignant neoplasm progression, Jaundice cholestatic, Overdose, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, CABOZANTINIB, CABOZANTINIB, PREGABALIN, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, MORPHINE SULFATE, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, BURN RELIEF, MAXIMUM STRENGTH PAIN RELIEVER, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, LIDOCAINE 4%, LIDOCAINE, MENTHOL, FUROSEMIDE, GLYCOPYRROLATE, LANSOPRAZOLE, DOCUSATE SODIUM, DOCUSATE SODIUM 100MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, LORAZEPAM, MIDAZOLAM, MIDAZOLAM HYDROCHLORIDE, MORPHINE SULFATE, PREGABALIN, PREGABALIN, |
||||
| 621 | 25008333 |
IN |
40 | 2 |
Malignant neoplasm progression, Product use in unapproved indication, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CARBOPLATIN, CARBOPLATIN, FLUOROURACIL, |
||||
| 622 | 25008383 |
US |
||
Malignant neoplasm progression, |
||||
FULVESTRANT, FULVESTRANT, |
||||
| 623 | 25009722 |
GB |
19 | 1 |
Pancreatitis acute, Jaundice cholestatic, Malignant neoplasm progression, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, CABOZANTINIB, CABOZANTINIB, PREGABALIN, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, |
||||
| 624 | 25010076 |
JP |
1 | |
Malignant neoplasm progression, Rash, Pneumonia aspiration, Therapeutic product effect incomplete, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, |
||||
| 625 | 25010258 |
US |
||
Hepatotoxicity, Malignant neoplasm progression, Drug ineffective, |
||||
ABEMACICLIB, |
||||
| 626 | 25010729 |
JP |
81 | 1 |
Malignant neoplasm progression, Device related infection, Pyrexia, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, |
||||
| 627 | 25010739 |
JP |
82 | 1 |
Malignant neoplasm progression, Cytokine release syndrome, |
||||
PEMBROLIZUMAB, GEMCITABINE HYDROCHLORIDE, CISPLATIN, |
||||
| 628 | 25010984 |
US |
63 | 1 |
Malignant neoplasm progression, Candida infection, Influenza, |
||||
NIVOLUMAB, CABOZANTINIB, OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, OSELTAMIVIR PHOSPHATE, |
||||
| 629 | 25001801 |
GE |
55 | 2 |
Electrocardiogram QT prolonged, Hormone receptor positive HER2 negative breast cancer, Malignant neoplasm progression, |
||||
RIBOCICLIB, RIBOCICLIB, LETROZOLE, LETROZOLE TABLETS, HALOPERIDOL, HALOPERIDOL LACTATE, |
||||
| 630 | 25001925 |
US |
||
Malignant neoplasm progression, |
||||
SELPERCATINIB, |
||||
| 631 | 25002134 |
CA |
39 | 2 |
Disease recurrence, Immune thrombocytopenia, Malignant neoplasm progression, Platelet count decreased, Product use in unapproved indication, |
||||
HUMAN IMMUNOGLOBULIN G, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, RITUXIMAB, RITUXIMAB, |
||||
| 632 | 25002208 |
JP |
60 | 2 |
Malignant neoplasm progression, Immune-mediated hypothyroidism, |
||||
PEMBROLIZUMAB, |
||||
| 633 | 25002593 |
US |
75 | 1 |
Malignant neoplasm progression, |
||||
ENZALUTAMIDE, |
||||
| 634 | 25002890 |
JM |
72 | 1 |
Cardiac failure acute, Septic shock, Deep vein thrombosis, Pulmonary embolism, Peripheral swelling, Dysuria, Urine odour abnormal, Dyspnoea, Urinary tract infection, Pyrexia, Gastrointestinal stromal tumour, Malignant neoplasm progression, Acute respiratory distress syndrome, Upper gastrointestinal haemorrhage, Acute kidney injury, Urosepsis, Renal impairment, Dyspepsia, Leukocytosis, Nausea, Vomiting, Asthenia, Oedema peripheral, Anaemia, Hypotension, |
||||
ZOLEDRONIC ACID, FINASTERIDE, |
||||
| 635 | 25003296 |
PL |
77 | 2 |
Femur fracture, Malignant neoplasm progression, |
||||
LANREOTIDE ACETATE, LANREOTIDE ACETATE, |
||||
| 636 | 25003328 |
CA |
||
Malignant neoplasm progression, |
||||
ABIRATERONE ACETATE, ABIRATERONE, |
||||
| 637 | 25003557 |
SG |
57 | 1 |
Malignant neoplasm progression, Rash, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
| 638 | 25003787 |
US |
43 | 2 |
Malignant neoplasm progression, |
||||
DUPILUMAB, |
||||
| 639 | 25003824 |
GB |
||
Malignant neoplasm progression, Oedema peripheral, Abdominal distension, Pleural effusion, |
||||
DOSTARLIMAB, |
||||
| 640 | 25003933 |
GB |
2 | |
Deep vein thrombosis, Malignant neoplasm progression, Renal impairment, Therapy partial responder, |
||||
CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 641 | 25003945 |
JP |
9 | 1 |
Malignant neoplasm progression, Decreased activity, Drug ineffective, |
||||
PEMBROLIZUMAB, |
||||
| 642 | 25004491 |
EG |
28 | 1 |
Malignant neoplasm progression, General physical health deterioration, |
||||
TRIFLURIDINE AND TIPIRACIL, |
||||
| 643 | 25004788 |
JP |
7 | 1 |
Malignant neoplasm progression, Renal impairment, |
||||
PEMBROLIZUMAB, |
||||
| 644 | 25005172 |
CA |
60 | 1 |
Blister, Blood thyroid stimulating hormone decreased, Bone density increased, Decreased appetite, Diarrhoea, Hepatic mass, Hyperkeratosis, Malignant neoplasm progression, Mobility decreased, Nodule, Skin discolouration, Weight decreased, Gingival ulceration, |
||||
LENVATINIB, CABOZANTINIB, CABOZANTINIB, NICOTINAMIDE, NIFEDIPINE, ROSUVASTATIN CALCIUM, LEVOTHYROXINE SODIUM, |
||||
| 645 | 25005392 |
JP |
57 | 2 |
Schizophrenia, Central hypothyroidism, Malignant neoplasm progression, Thyroiditis subacute, |
||||
PEMBROLIZUMAB, |
||||
| 646 | 25005534 |
63 | ||
Cardiac failure, Malignant neoplasm progression, Atrial flutter, |
||||
OSIMERTINIB, |
||||
| 647 | 25005680 |
NZ |
7 | 1 |
Radiation necrosis, Malignant neoplasm progression, Diarrhoea, Off label use, |
||||
ABEMACICLIB, |
||||
| 648 | 25005877 |
HR |
57 | 2 |
Death, Panniculitis, Metastatic malignant melanoma, Metastases to central nervous system, Malignant neoplasm progression, Skin mass, Neoplasm progression, |
||||
DABRAFENIB, DABRAFENIB, TRAMETINIB, TRAMETINIB, PEMBROLIZUMAB, |
||||
| 649 | 25006020 |
JP |
61 | 2 |
Malignant neoplasm progression, Thrombocytopenia, Cardiac failure, Immune-mediated hypothyroidism, Malaise, Proteinuria, Hypertension, Headache, Proteinuria, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 650 | 25006061 |
JP |
1 | |
Cytokine release syndrome, Oesophageal perforation, Nephritis, Pneumonia, Pneumonia aspiration, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, CISPLATIN, FLUOROURACIL, |
||||
| 651 | 25006242 |
US |
52 | 2 |
Malignant neoplasm progression, |
||||
LENALIDOMIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ALBUTEROL SULFATE, CLONAZEPAM, PEGCETACOPLAN, EMPAGLIFLOZIN, FUROSEMIDE, PROGESTERONE, TOPIRAMATE, TOPIRAMATE SPINKLE, |
||||
| 652 | 25006259 |
CN |
||
Adverse event, Malignant neoplasm progression, Respiratory failure, Cerebral infarction, Metastases to meninges, Hypokalaemia, Pneumonia, White blood cell count decreased, Neutrophil count decreased, Aspartate aminotransferase increased, Alanine aminotransferase increased, Lymphocyte count decreased, Toothache, Decreased appetite, Anaemia, Platelet count decreased, Nausea, Asthenia, Diarrhoea, Hypocalcaemia, Hypophosphataemia, |
||||
DENOSUMAB, ERGOCALCIFEROL, CALCIUM, |
||||
| 653 | 25006298 |
JP |
2 | |
Malignant neoplasm progression, Depressed level of consciousness, |
||||
PEMBROLIZUMAB, PACLITAXEL, |
||||
| 654 | 25006531 |
BE |
||
Malignant neoplasm progression, |
||||
DURVALUMAB, CARBOPLATIN, PACLITAXEL, |
||||
| 655 | 25001367 |
US |
||
Liver function test increased, Malignant neoplasm progression, |
||||
ALECTINIB HYDROCHLORIDE, |
||||
| 656 | 24992590 |
JP |
72 | 2 |
Malignant neoplasm progression, Type 1 diabetes mellitus, Platelet count decreased, Erythema, Off label use, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 657 | 24992838 |
JP |
77 | 1 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, AXITINIB, |
||||
| 658 | 24993448 |
JP |
8 | 1 |
Death, Malignant neoplasm progression, Leukoderma, |
||||
PEMBROLIZUMAB, NIVOLUMAB, |
||||
| 659 | 24993898 |
GB |
29 | 2 |
Death, Malignant neoplasm progression, Alanine aminotransferase increased, Abdominal pain, Muscle spasms, Off label use, |
||||
CABOZANTINIB, CABOZANTINIB, APIXABAN, LANSOPRAZOLE, MORPHINE SULFATE, |
||||
| 660 | 24993924 |
TR |
64 | 1 |
Death, Spinal compression fracture, Malignant neoplasm progression, Blood creatinine increased, Prostatic specific antigen increased, Urine output decreased, General physical health deterioration, |
||||
ENZALUTAMIDE, LEUPROLIDE ACETATE, LINAGLIPTIN, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, BICALUTAMIDE, |
||||
| 661 | 24994003 |
JP |
1 | |
Malignant neoplasm progression, |
||||
BEXAROTENE, |
||||
| 662 | 24994111 |
US |
52 | 1 |
Malignant neoplasm progression, Pleural effusion, Mucosal inflammation, Diarrhoea, Abdominal pain, |
||||
NIVOLUMAB, CABOZANTINIB, |
||||
| 663 | 24994659 |
BR |
2 | |
Malignant neoplasm progression, Daydreaming, Dyspnoea, |
||||
RIBOCICLIB, |
||||
| 664 | 24995006 |
RU |
||
Anaplastic thyroid cancer, Malignant neoplasm progression, |
||||
DABRAFENIB, TRAMETINIB, |
||||
| 665 | 24995471 |
JP |
65 | 2 |
Death, Malignant neoplasm progression, Large intestine perforation, |
||||
PEMBROLIZUMAB, |
||||
| 666 | 24995828 |
JP |
52 | 2 |
Malignant neoplasm progression, Myalgia, |
||||
PEMBROLIZUMAB, LENVATINIB, LENVATINIB, |
||||
| 667 | 24995850 |
IL |
62 | 2 |
Malignant neoplasm progression, Pelvic pain, Back pain, Abdominal pain, |
||||
TRIFLURIDINE AND TIPIRACIL, |
||||
| 668 | 24996245 |
BG |
66 | 1 |
Malignant neoplasm progression, |
||||
ENZALUTAMIDE, DENOSUMAB, |
||||
| 669 | 24997060 |
GB |
2 | |
Blindness, Deafness, Malignant neoplasm progression, Vasculitis, |
||||
PEMBROLIZUMAB, |
||||
| 670 | 25003356 |
77 | 2 | |
Pancreatic carcinoma, Malignant neoplasm progression, |
||||
PANCRELIPASE, |
||||
| 671 | 24988157 |
US |
||
Malignant neoplasm progression, |
||||
FULVESTRANT, FULVESTRANT, FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 672 | 24988440 |
US |
2 | |
Malignant neoplasm progression, Diarrhoea, Nausea, Vomiting, |
||||
ABEMACICLIB, NERATINIB, CAPECITABINE, |
||||
| 673 | 24988543 |
FR |
86 | 2 |
Neurodermatitis, Malignant neoplasm progression, |
||||
CARBOPLATIN, CARBOPLATIN, PACLITAXEL, PACLITAXEL, DOSTARLIMAB, DOSTARLIMAB, DOSTARLIMAB, |
||||
| 674 | 24988699 |
SG |
||
Malignant neoplasm progression, |
||||
ZANUBRUTINIB, |
||||
| 675 | 24988833 |
DE |
87 | |
Urinary retention, Cytokine release syndrome, Malignant neoplasm progression, Off label use, |
||||
LENALIDOMIDE, GLOFITAMAB, |
||||
| 676 | 24989005 |
US |
60 | 1 |
Acute disseminated encephalomyelitis, Malignant neoplasm progression, Drug ineffective for unapproved indication, |
||||
AZACITIDINE, AZACITIDINE FOR, VENETOCLAX, |
||||
| 677 | 24989130 |
JP |
7 | 1 |
Malignant neoplasm progression, Meningitis, Hepatic function abnormal, |
||||
PEMBROLIZUMAB, PEMETREXED DISODIUM, PEMETREXED, CARBOPLATIN, |
||||
| 678 | 24989226 |
CN |
61 | 1 |
Malignant neoplasm progression, |
||||
MEGESTROL ACETATE, |
||||
| 679 | 24989345 |
FR |
60 | 2 |
Pyelonephritis, Malignant neoplasm progression, Streptococcal bacteraemia, Dermo-hypodermitis, Arthritis bacterial, Myocarditis, Polyneuropathy, Immunotoxicity, General physical health deterioration, |
||||
CARBOPLATIN, CARBOPLATIN, PACLITAXEL, PACLITAXEL, DOSTARLIMAB, DOSTARLIMAB, |
||||
| 680 | 24989438 |
CA |
2 | |
Ovarian cancer, Malignant neoplasm progression, Ovarian cancer recurrent, Off label use, |
||||
LETROZOLE, LETROZOLE TABLETS, PACLITAXEL, CARBOPLATIN, BEVACIZUMAB, TRAMETINIB, TRAMETINIB, |
||||
| 681 | 24989469 |
FR |
1 | |
Malignant neoplasm progression, Pneumonia, Product use in unapproved indication, |
||||
CARBOPLATIN, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, CETUXIMAB, ACEBUTOLOL HYDROCHLORIDE, DOXYCYCLINE, DOXYCYCLINE HYCLATE, |
||||
| 682 | 24989578 |
JP |
7 | 1 |
Immune-mediated hepatic disorder, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, |
||||
| 683 | 24989945 |
JP |
82 | |
Malignant neoplasm progression, |
||||
DURVALUMAB, |
||||
| 684 | 24990141 |
JP |
62 | 1 |
Malignant neoplasm progression, Stevens-Johnson syndrome, |
||||
PEMBROLIZUMAB, |
||||
| 685 | 24990451 |
CA |
||
Malignant neoplasm progression, Breast cancer metastatic, Carcinoembryonic antigen increased, Drug intolerance, Mood swings, Injection site pain, |
||||
GOSERELIN, GOSERELIN, FULVESTRANT, ALPELISIB, RIBOCICLIB, RELUGOLIX, |
||||
| 686 | 24990736 |
HU |
63 | 2 |
Osteonecrosis of jaw, Malignant neoplasm progression, |
||||
TRASTUZUMAB, |
||||
| 687 | 24990838 |
JP |
1 | |
Malignant neoplasm progression, |
||||
LENVATINIB, PEMBROLIZUMAB, |
||||
| 688 | 24990880 |
JP |
67 | 2 |
Cholecystitis, Malignant neoplasm progression, Gastritis, |
||||
PEMBROLIZUMAB, PACLITAXEL, CARBOPLATIN, BEVACIZUMAB, |
||||
| 689 | 24990985 |
JP |
7 | 1 |
Diverticulitis, Malignant neoplasm progression, Adrenocorticotropic hormone deficiency, Therapy partial responder, |
||||
PEMBROLIZUMAB, CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 690 | 24991097 |
GB |
||
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 691 | 24991300 |
PL |
||
Blood bilirubin increased, Malignant neoplasm progression, |
||||
IVOSIDENIB, |
||||
| 692 | 24991498 |
RU |
||
Anaplastic thyroid cancer, Malignant neoplasm progression, Therapy non-responder, |
||||
DABRAFENIB, TRAMETINIB, |
||||
| 693 | 24991502 |
RU |
||
Anaplastic thyroid cancer, Malignant neoplasm progression, Therapy non-responder, |
||||
DABRAFENIB, TRAMETINIB, |
||||
| 694 | 24991584 |
US |
||
Malignant neoplasm progression, Drug ineffective, |
||||
VORASIDENIB, |
||||
| 695 | 24991874 |
JP |
9 | 2 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, CAPECITABINE, OXALIPLATIN, |
||||
| 696 | 24991923 |
BR |
1 | |
Asthenia, Decreased appetite, Malignant neoplasm progression, Off label use, |
||||
CETUXIMAB, |
||||
| 697 | 24992240 |
JP |
7 | 2 |
Malignant neoplasm progression, Electrocardiogram ST segment depression, Defect conduction intraventricular, Shock, Nephropathy toxic, Hypothyroidism, Nausea, Weight decreased, Acute kidney injury, Immune-mediated adrenal insufficiency, Ureteric stenosis, Hydronephrosis, Electrocardiogram QT prolonged, Decreased appetite, Dehydration, Eastern Cooperative Oncology Group performance status worsened, Palmar-plantar erythrodysaesthesia syndrome, Infusion related reaction, Hyponatraemia, Constipation, Diarrhoea, Cancer pain, Depressive symptom, Cystitis bacterial, Headache, Hypertension, Malaise, Therapeutic product effect incomplete, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 698 | 24992508 |
IT |
||
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 699 | 24994619 |
68 | 2 | |
Lung neoplasm malignant, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 700 | 24983302 |
GB |
2 | |
Deep vein thrombosis, Therapy partial responder, Malignant neoplasm progression, Renal impairment, |
||||
CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28